Diabetic Cardiomyopathy: a Brief Summary on Lipid Toxicity

Overview

Journal ESC Heart Fail

Date 2022 Nov 12

PMID 36369594

Authors

Jiahan Ke

Jianan Pan

Hao Lin

Jun Gu

Affiliations

Soon will be listed here.

Abstract

Diabetes mellitus (DM) is a serious epidemic around the globe, and cardiovascular diseases account for the majority of deaths in patients with DM. Diabetic cardiomyopathy (DCM) is defined as a cardiac dysfunction derived from DM without the presence of coronary artery diseases and hypertension. Patients with either type 1 or type 2 DM are at high risk of developing DCM and even heart failure. Metabolic disorders of obesity and insulin resistance in type 2 diabetic environments result in dyslipidaemia and subsequent lipid-induced toxicity (lipotoxicity) in organs including the heart. Although various mechanisms have been proposed underlying DCM, it remains incompletely understood how lipotoxicity alters cardiac function and how DM induces clinical heart syndrome. With recent progress, we here summarize the latest discoveries on lipid-induced cardiac toxicity in diabetic hearts and discuss the underlying therapies and controversies in clinical DCM.

Citing Articles

Cardioprotective Effect of Nigella sativa in Pediatric Patients with Type 1 Diabetes Mellitus: A Randomized Controlled Study.

El-Afify D, El Amrousy D Paediatr Drugs. 2025; .

PMID: 40048139 DOI: 10.1007/s40272-025-00687-5.

Inhibition of high glucose-induced cardiac fibroblast activation: an effective treatment for diabetic cardiomyopathy using Chinese herbal medicine.

Wan B, Hu J, Luo Y, Han Y, Zhang Y, Huang Q Front Pharmacol. 2025; 16:1523014.

PMID: 39931690 PMC: 11808154. DOI: 10.3389/fphar.2025.1523014.

Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy-Challenges and Prospectives.

Khattab E, Kyriakou M, Leonidou E, Sokratous S, Mouzarou A, Myrianthefs M Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861195 PMC: 11768626. DOI: 10.3390/ph18010134.

Empagliflozin in diabetic cardiomyopathy: elucidating mechanisms, therapeutic potentials, and future directions.

Jaiswal A, Yadav P, Rawat P, Kaur M, Babu S, Khurana A Mol Biol Rep. 2025; 52(1):158.

PMID: 39853512 DOI: 10.1007/s11033-025-10260-5.

Cardioprotective Effects of 'Vasant Kusumakar Rasa,' a Herbo-metallic Formulation, in Type 2 Diabetic Cardiomyopathy in Rats.

Singh A, Chawda M, Kulkarni Y Cardiovasc Toxicol. 2024; 24(9):942-954.

PMID: 39023814 DOI: 10.1007/s12012-024-09891-0.

References

Singh R, Cuervo A . Autophagy in the cellular energetic balance. Cell Metab. 2011; 13(5):495-504. PMC: 3099265. DOI: 10.1016/j.cmet.2011.04.004. View

Belousov D, Mikhaylenko E, Somasundaram S, Kirkland C, Aliev G . The Dawn of Mitophagy: What Do We Know by Now?. Curr Neuropharmacol. 2020; 19(2):170-192. PMC: 8033973. DOI: 10.2174/1570159X18666200522202319. View

Wilson A, Gill E, Abudalo R, Edgar K, Watson C, Grieve D . Reactive oxygen species signalling in the diabetic heart: emerging prospect for therapeutic targeting. Heart. 2017; 104(4):293-299. DOI: 10.1136/heartjnl-2017-311448. View

Wang P, Liu J, Li Y, Wu S, Luo J, Yang H . Peroxisome proliferator-activated receptor {delta} is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart. Circ Res. 2010; 106(5):911-9. PMC: 2993321. DOI: 10.1161/CIRCRESAHA.109.206185. View

Martinez-Lopez N, Garcia-Macia M, Sahu S, Athonvarangkul D, Liebling E, Merlo P . Autophagy in the CNS and Periphery Coordinate Lipophagy and Lipolysis in the Brown Adipose Tissue and Liver. Cell Metab. 2015; 23(1):113-27. PMC: 4715637. DOI: 10.1016/j.cmet.2015.10.008. View

Finck B, Lehman J, Leone T, Welch M, Bennett M, Kovacs A . The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002; 109(1):121-30. PMC: 150824. DOI: 10.1172/JCI14080. View

Pu J, Ha C, Zhang S, Jung J, Huh W, Liu P . Interactomic study on interaction between lipid droplets and mitochondria. Protein Cell. 2011; 2(6):487-96. PMC: 4875178. DOI: 10.1007/s13238-011-1061-y. View

Liu Q, Chen X, MacDonnell S, Kranias E, Lorenz J, Leitges M . Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ Res. 2009; 105(2):194-200. PMC: 2749656. DOI: 10.1161/CIRCRESAHA.109.195313. View

Steinberg S . Oxidative stress and sarcomeric proteins. Circ Res. 2013; 112(2):393-405. PMC: 3595003. DOI: 10.1161/CIRCRESAHA.111.300496. View

10.

Stenlof K, Cefalu W, Kim K, Alba M, Usiskin K, Tong C . Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15(4):372-82. PMC: 3593184. DOI: 10.1111/dom.12054. View

11.

Kannel W, Hjortland M, CASTELLI W . Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34(1):29-34. DOI: 10.1016/0002-9149(74)90089-7. View

12.

Rijzewijk L, van der Meer R, Lamb H, W A M de Jong H, Lubberink M, Romijn J . Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009; 54(16):1524-32. DOI: 10.1016/j.jacc.2009.04.074. View

13.

Scheen A . Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res. 2018; 122(10):1439-1459. PMC: 5959222. DOI: 10.1161/CIRCRESAHA.117.311588. View

14.

Boudina S, Sena S, Theobald H, Sheng X, Wright J, Hu X . Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes. 2007; 56(10):2457-66. DOI: 10.2337/db07-0481. View

15.

de Simone G, Devereux R, Chinali M, Lee E, Galloway J, Barac A . Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J Hypertens. 2009; 28(2):353-60. PMC: 3005764. DOI: 10.1097/HJH.0b013e3283331169. View

16.

Tong M, Saito T, Zhai P, Oka S, Mizushima W, Nakamura M . Alternative Mitophagy Protects the Heart Against Obesity-Associated Cardiomyopathy. Circ Res. 2021; 129(12):1105-1121. DOI: 10.1161/CIRCRESAHA.121.319377. View

17.

Chen Y, Liu Y, Dorn 2nd G . Mitochondrial fusion is essential for organelle function and cardiac homeostasis. Circ Res. 2011; 109(12):1327-31. PMC: 3237902. DOI: 10.1161/CIRCRESAHA.111.258723. View

18.

White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-35. DOI: 10.1056/NEJMoa1305889. View

19.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

20.

Huynh K, Kiriazis H, Du X, Love J, Gray S, Jandeleit-Dahm K . Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radic Biol Med. 2013; 60:307-17. DOI: 10.1016/j.freeradbiomed.2013.02.021. View